Atika Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Atika Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-153,000	Closed	-$14.1M	–	108
2021 Q4	$17.1M	Buy	153,000 +36,000	+31%	+$4.34M	1.2%	39
2021 Q3	$14.7M	Buy	+117,000	New	+$15.1M	0.88%	42

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Atika Capital Management's XBI Position: Q1 2022 in Review

Atika Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2022, closing a stake of 153,000 shares — an estimated $14.1M sold.

Atika Capital Management first reported a position in XBI in Q3 2021 and held it in 2 quarters. The position peaked at $17.1M in Q4 2021. 703 funds tracked by Wall St. Rank hold XBI as of Q1 2022.

Atika Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2022 after selling out during the quarter.
Atika Capital Management sold 153,000 State Street SPDR S&P Biotech ETF shares in Q1 2022, an estimated $14.1M.
Atika Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2021 and held it in 2 quarters.
Atika Capital Management's State Street SPDR S&P Biotech ETF position peaked at $17.1M in Q4 2021.
703 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2022.

Based on Atika Capital Management's 13F filing for Q1 2022, filed 13 May 2022.